Telavancin matches vancomycin for SSSIs but has more side effects

10/18/2011 | SkinAndAllergyNews.com

Telavancin and vancomycin had similar cure rates, 72% and 73%, respectively, for skin and skin structure infections in obese patients, though the serious adverse event rate was higher in the telavancin group (11% compared with 3%), according to an analysis of two late-stage trials.

View Full Article in:

SkinAndAllergyNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA